Company Interview / The Aussie small cap tuning into China

Key points:

Audeara (ASX:AUA) gains regulatory approval to sell hearing aids in China Company leverages high-margin licensing model and strong regional partnerships Partnership and compatibility with Cochlear (ASX:COH) and market potential versus Apple (NASDAQ: AAPL) Dr James Fielding considers Audeara undervalued given business progress

Dr James Fielding from Audeara highlights major progress as the company secures regulatory approval to sell hearing aids in China, the second biggest market globally. Fielding views this certification as a key milestone, transforming Audeara’s offerings from consumer-level devices to recognised medical-grade technology. He emphasises the significance of tapping into the vast Chinese market through a licensing and solutions model, enabling high margins and minimal regulatory risk. Fielding states that existing partnerships in the region allow Audeara (ASX:AUA) to scale efficiently, leveraging local expertise for market penetration.

Audeara aims to position itself alongside industry giants such as Cochlear (ASX:COH) and global competitors like Apple ($AAPL), whose move into hearing technology has expanded opportunities for Audeara’s licensing business. Fielding mentions collaborations with Cochlear and highlights how Audeara’s headphones integrate with cochlear implant systems. The recent creation of an AÜA Tech division focuses on licensing deals, targeting hearing aid manufacturers worldwide eager to match Apple’s advancements.

Fielding also notes the company’s solid wholesale margins of around 50% in Australia, and ongoing support from government initiatives, including a $1.2 million R&D tax incentive. Audeara’s stock is currently trading around $0.03, down from its listing price, but Fielding considers the business to be undervalued relative to its achievements since listing.